Brokerages Set NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Price Target at $1.98

Shares of NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) have been given a consensus recommendation of “Hold” by the five brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $1.9833.

A number of research analysts have weighed in on NMTC shares. Zacks Research downgraded shares of NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 13th. Wall Street Zen upgraded NeuroOne Medical Technologies to a “sell” rating in a research report on Saturday, February 21st. Finally, JonesTrading began coverage on NeuroOne Medical Technologies in a report on Monday, March 2nd. They issued a “buy” rating and a $1.50 price target for the company.

Insider Buying and Selling

In other NeuroOne Medical Technologies news, insider David J. Wambeke acquired 1,000,000 shares of the business’s stock in a transaction dated Sunday, March 1st. The stock was acquired at an average cost of $0.67 per share, for a total transaction of $670,000.00. Following the completion of the transaction, the insider directly owned 1,000,000 shares of the company’s stock, valued at $670,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 14,637 shares of company stock valued at $11,710 over the last quarter. 11.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Focus Financial Network Inc. acquired a new stake in NeuroOne Medical Technologies in the 3rd quarter valued at $31,000. Legato Capital Management LLC acquired a new position in NeuroOne Medical Technologies during the fourth quarter worth $34,000. Squarepoint Ops LLC acquired a new position in NeuroOne Medical Technologies during the fourth quarter worth $36,000. Susquehanna International Group LLP purchased a new position in NeuroOne Medical Technologies during the third quarter valued at $47,000. Finally, XTX Topco Ltd lifted its holdings in NeuroOne Medical Technologies by 321.1% during the fourth quarter. XTX Topco Ltd now owns 85,454 shares of the company’s stock valued at $65,000 after purchasing an additional 65,163 shares in the last quarter. Hedge funds and other institutional investors own 16.07% of the company’s stock.

NeuroOne Medical Technologies Price Performance

NASDAQ:NMTC opened at $0.73 on Friday. The firm has a market cap of $37.09 million, a price-to-earnings ratio of -4.32 and a beta of 0.74. The company has a 50 day moving average price of $0.78 and a 200-day moving average price of $0.79. NeuroOne Medical Technologies has a 1-year low of $0.40 and a 1-year high of $1.16.

NeuroOne Medical Technologies (NASDAQ:NMTC) last announced its quarterly earnings results on Tuesday, February 17th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. The firm had revenue of $2.89 million for the quarter, compared to the consensus estimate of $2.47 million. NeuroOne Medical Technologies had a negative net margin of 78.34% and a negative return on equity of 119.92%.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.